Business Wire

Stellantis Joins GlobalPlatform to Advance Global Automotive Cybersecurity Standards

4.9.2025 15:00:00 CEST | Business Wire | Press Release

Share

Stellantis is the latest major auto OEM to join GlobalPlatform, helping to accelerate cross-industry collaboration on cybersecurity standardization for software-defined vehicles (SDVs).

Stellantis—the company behind 14 major auto brands, including Alfa Romeo, Chrysler, FIAT, Jeep®, Opel, Peugeot, and Vauxhall—has joined GlobalPlatform to help align its technologies with evolving automotive use cases and regulatory requirements. As part of the agreement, Bill Mazzara, North American Regulatory Lead and Technical Fellow for Product Cybersecurity at Stellantis, becomes co-chair of the GlobalPlatform Automotive Task Force.

Stellantis joins a growing community of automakers, cybersecurity firms, silicon vendors, and academic institutions in GlobalPlatform that are advancing a standardized approach to meeting the complex cybersecurity demands of today’s SDVs. Recent members of the Automotive Task Force include AIST, Cariad (Volkswagen), Dekra, ETAS, Linaro, Rambus, Renesas, Stellantis, Uni-sentry, and Woven by Toyota.

“GlobalPlatform’s Automotive Task Force is helping the industry converge on a platform of secure, scalable foundations for software-defined vehicles,” said Bill Mazzara. “Our engagement is focused on harmonizing security standards and fostering cross-industry collaboration to meet evolving regulatory and operational requirements and ultimately our customers' expectations.”

The Automotive Task Force is at the forefront of bringing market-proven GlobalPlatform technologies and specifications to the automotive sector. It recently reached a major milestone by fully aligning these specifications with the new addendum of the SAE J3101 Hardware Protected Security Environment automotive cybersecurity standard (J3101-5). This creates the formal means for GlobalPlatform-compliant suppliers to demonstrate automatic compliance with J3101. It provides automakers with confidence that components embedded in their vehicles meet cybersecurity requirements and facilitate integration with applications of AutoSAR, Car Connectivity Consortium, and other automotive frameworks.

The Automotive Task Force has also developed a protection profile based on the SESIP evaluation methodology to ensure component-level certifications are aligned with SAE J3101. This allows certified components to be reused across platforms without the need for re-evaluation, saving time and resources across the supply chain.

“Stellantis’ participation in GlobalPlatform reflects our commitment to advancing standardized, secure technologies that can scale across the automotive ecosystem,” said Muttalip Akin, SVP, Head of Electrical, Electronic & Hardware Engineering, Stellantis.

“These recent advancements represent a breakthrough in the industry’s goal of creating a standardized and certified platform for secure vehicle applications,” said Ana Tavares Lattibeaudiere, Executive Director, GlobalPlatform. “We urge further companies from across the auto industry to join us in our mission to lower risk, reduce costs, and eliminate fragmentation across the automotive cybersecurity ecosystem.”

About GlobalPlatform
GlobalPlatform is a technical standards organization that enables the efficient launch and management of innovative, secure-by-design digital services and devices. GlobalPlatform technologies are used in billions of smart cards, smartphones, wearables and other connected and IoT devices.

GlobalPlatform standardized technologies and certifications are developed through effective industry-driven collaboration, led by multiple diverse member companies working in partnership with industry and regulatory bodies and other interested parties from around the world.

globalplatform.org

View source version on businesswire.com: https://www.businesswire.com/news/home/20250828443903/en/

Contacts

For further media information:
Matt Ablott
mablott@combustion.marketing

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye